Hikma Pharmaceuticals (LSE:HIK) maintained its full-year 2026 outlook following a strong performance across its Injectables, Branded, and Hikma Rx divisions. The group expects revenue growth of 2% to 4% and operating profit in the range of $720 million to $770 million, supported by solid demand, recent product launches, and increased manufacturing capacity. Margins are expected to remain stable across all divisions, while the company continues to wind down its non-core 503B compounding operations.
Inhalation Strategy and Product Development Progress
Management highlighted ongoing advancements in its complex inhalation portfolio, including a new device partnership aimed at accelerating its generic Ellipta programme. Continued contributions from products such as generic Advair Diskus also reflect the company’s growing presence in differentiated respiratory treatments. Alongside these developments, Hikma reaffirmed its commitment to shareholder returns, announcing a 5% increase in its total dividend for 2025 and continuing its share buyback programme of up to $250 million, while remaining mindful of geopolitical risks in the Middle East and rising logistics and energy costs.
Outlook Balanced by Cash Flow and Market Signals
The company’s outlook is tempered by softer cash generation and a bearish technical trend, with the stock trading below key moving averages and showing oversold conditions. However, these challenges are partly offset by an attractive valuation, including a relatively low price-to-earnings ratio and a strong dividend yield. Management’s positive earnings guidance and ongoing capital return programme provide additional support, despite near-term pressures in the injectables segment.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals is a UK-based multinational pharmaceutical company focused on developing, manufacturing, and marketing a wide range of branded and generic medicines. With operations spanning North America, the Middle East and North Africa, and Europe, the group specialises in injectables, branded treatments, and prescription generics, supported by strong manufacturing capabilities, licensing partnerships, and expertise in inhalation technologies.
Leave a Reply